Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 7/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5591690 | 0.88 | HCAR3 (0.56) | HCAR3MAPTALDH1A1PKMRAB9A | |
| SCHEMBL14457839 | 0.83 | MAPT (0.53) | HCAR3MAPTALDH1A1PKMRAB9A | |
| SCHEMBL5104664 | 0.82 | PTGER4 (0.43) | MAPTALDH1A1THRBPRSS1PTGER4 | |
| SCHEMBL7230677 | 0.81 | HCAR3 (0.59) | HCAR3MAPTALDH1A1PKMRAB9A | |
| SCHEMBL5095799 | 0.79 | HCAR3 (0.48) | HCAR3MAPTALDH1A1RAB9ANPC1 | |
| SCHEMBL14459959 | 0.78 | TSHR (0.56) | MAPTALDH1A1PKMRAB9ANPC1 | |
| SCHEMBL5095726 | 0.77 | POLB (0.46) | HCAR3MAPTALDH1A1PKMCRHBP | |
| SCHEMBL5095722 | 0.77 | HCAR3 (0.49) | HCAR3MAPTALDH1A1RAB9ANPC1 | |
| SCHEMBL5095713 | 0.77 | HCAR3 (0.49) | HCAR3MAPTALDH1A1RAB9ANPC1 | |
| SCHEMBL5104752 | 0.77 | MAPT (0.48) | HCAR3MAPTALDH1A1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7407968-B2 | Compounds | ASTRAZENECA AB (SE) | 2008-08-05 | — | — | US | disclosed |
| US-7407968-B2 | Compounds | ASTRAZENECA AB (SE) | 2008-08-05 | — | — | US | disclosed |
| US-7407968-B2 | Compounds | ASTRAZENECA AB (SE) | 2008-08-05 | — | — | US | disclosed |
| WO-2007091950-A1 | BENZIMIDAZOLES AND IMIDAZOPYRIDINES USEFUL IN THE TREATMENT OF DISEASES OR DISORDERS ASSOCIATED WITH CANNABINOID RECEPTOR 2 (CB2) SUCH AS PAIN | ASTRAZENECA AB (SE) | 2007-08-16 | — | — | WO | disclosed |
| US-20070105893-A1 | Novel Compounds | ASTRAZENECA AB R&D HEADQUARTERS GLOBAL INTELLECTUAL PROPERTY PATENTS (SE) | 2007-05-10 | — | — | US | disclosed |
| US-20070105893-A1 | Novel Compounds | ASTRAZENECA AB R&D HEADQUARTERS GLOBAL INTELLECTUAL PROPERTY PATENTS (SE) | 2007-05-10 | — | — | US | disclosed |
| US-20070105893-A1 | Novel Compounds | ASTRAZENECA AB R&D HEADQUARTERS GLOBAL INTELLECTUAL PROPERTY PATENTS (SE) | 2007-05-10 | — | — | US | disclosed |
| EP-1554254-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004035548-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105893-A1 | Novel Compounds | CNR1, CNR2, OPRL1 | HCAR3 424/4885MAPT 2943/4885ALDH1A1 2405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.